- Home
- LMB vs CVAC Comparison
LMB vs CVAC Comparison
Compare LMB & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- CVAC
- Stock Information
- Founded
- LMB 1901
- CVAC 2000
- Country
- LMB United States
- CVAC Germany
- Employees
- LMB N/A
- CVAC N/A
- Industry
- LMB Engineering & Construction
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- CVAC Health Care
- Exchange
- LMB Nasdaq
- CVAC Nasdaq
- Market Cap
- LMB 1.1B
- CVAC 924.3M
- IPO Year
- LMB 2014
- CVAC 2020
- Fundamental
- Price
- LMB $99.56
- CVAC $4.14
- Analyst Decision
- LMB Strong Buy
- CVAC Hold
- Analyst Count
- LMB 2
- CVAC 3
- Target Price
- LMB $106.50
- CVAC $10.00
- AVG Volume (30 Days)
- LMB 178.1K
- CVAC 1.2M
- Earning Date
- LMB 03-12-2025
- CVAC 11-12-2024
- Dividend Yield
- LMB N/A
- CVAC N/A
- EPS Growth
- LMB 29.01
- CVAC N/A
- EPS
- LMB 2.18
- CVAC N/A
- Revenue
- LMB $517,822,000.00
- CVAC $70,565,734.00
- Revenue This Year
- LMB $2.59
- CVAC $742.57
- Revenue Next Year
- LMB $12.46
- CVAC N/A
- P/E Ratio
- LMB $45.71
- CVAC N/A
- Revenue Growth
- LMB 0.13
- CVAC 75.11
- 52 Week Low
- LMB $38.03
- CVAC $2.22
- 52 Week High
- LMB $107.00
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- LMB 58.33
- CVAC 62.80
- Support Level
- LMB $91.28
- CVAC $3.89
- Resistance Level
- LMB $100.99
- CVAC $4.32
- Average True Range (ATR)
- LMB 5.93
- CVAC 0.34
- MACD
- LMB 0.53
- CVAC 0.01
- Stochastic Oscillator
- LMB 92.16
- CVAC 56.12
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.